vs
Cooper Companies (The)（COO）与梅特勒-托利多（MTD）财务数据对比。点击上方公司名可切换其他公司
梅特勒-托利多的季度营收约是Cooper Companies (The)的1.1倍（$1.1B vs $1.1B），梅特勒-托利多净利率更高（25.3% vs 7.9%，领先17.4%），梅特勒-托利多同比增速更快（8.1% vs 4.6%），梅特勒-托利多自由现金流更多（$184.1M vs $149.9M），过去两年梅特勒-托利多的营收复合增速更高（10.5% vs 6.9%）
CooperCompanies是总部位于美国加利福尼亚州圣拉蒙的全球医疗设备企业，旗下设有两大业务单元：主营隐形眼镜生产的库博光学，以及面向女性健康市场提供医疗设备、生育及基因组相关产品的库博外科。
梅特勒-托利多是全球知名的精密仪器及服务跨国供应商，业务覆盖实验室、工业生产、产品检测、食品零售等应用场景，旗下产品广泛应用于生命科学、食品、化工等众多行业的科研、质量管控及生产制造环节。
COO vs MTD — 直观对比
营收规模更大
MTD
是对方的1.1倍
$1.1B
营收增速更快
MTD
高出3.5%
4.6%
净利率更高
MTD
高出17.4%
7.9%
自由现金流更多
MTD
多$34.2M
$149.9M
两年增速更快
MTD
近两年复合增速
6.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $1.1B |
| 净利润 | $84.6M | $285.8M |
| 毛利率 | 61.1% | 59.8% |
| 营业利润率 | 13.2% | 29.1% |
| 净利率 | 7.9% | 25.3% |
| 营收同比 | 4.6% | 8.1% |
| 净利润同比 | -28.0% | 13.3% |
| 每股收益（稀释后） | $0.42 | $13.91 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收COOMTD
| Q4 25 | $1.1B | $1.1B | ||
| Q3 25 | $1.1B | $1.0B | ||
| Q2 25 | $1.0B | $983.2M | ||
| Q1 25 | $964.7M | $883.7M | ||
| Q4 24 | $1.0B | $1.0B | ||
| Q3 24 | $1.0B | $954.5M | ||
| Q2 24 | $942.6M | $946.8M | ||
| Q1 24 | $931.6M | $925.9M |
净利润COOMTD
| Q4 25 | $84.6M | $285.8M | ||
| Q3 25 | $98.3M | $217.5M | ||
| Q2 25 | $87.7M | $202.3M | ||
| Q1 25 | $104.3M | $163.6M | ||
| Q4 24 | $117.5M | $252.3M | ||
| Q3 24 | $104.7M | $211.5M | ||
| Q2 24 | $88.9M | $221.8M | ||
| Q1 24 | $81.2M | $177.5M |
毛利率COOMTD
| Q4 25 | 61.1% | 59.8% | ||
| Q3 25 | 65.3% | 59.2% | ||
| Q2 25 | 67.8% | 59.0% | ||
| Q1 25 | 68.4% | 59.5% | ||
| Q4 24 | 66.5% | 61.2% | ||
| Q3 24 | 66.1% | 60.0% | ||
| Q2 24 | 67.0% | 59.7% | ||
| Q1 24 | 67.0% | 59.2% |
营业利润率COOMTD
| Q4 25 | 13.2% | 29.1% | ||
| Q3 25 | 16.6% | 26.1% | ||
| Q2 25 | 18.4% | 25.3% | ||
| Q1 25 | 18.9% | 22.9% | ||
| Q4 24 | 19.5% | 30.1% | ||
| Q3 24 | 19.2% | 27.1% | ||
| Q2 24 | 17.2% | 25.7% | ||
| Q1 24 | 16.4% | 23.8% |
净利率COOMTD
| Q4 25 | 7.9% | 25.3% | ||
| Q3 25 | 9.3% | 21.1% | ||
| Q2 25 | 8.7% | 20.6% | ||
| Q1 25 | 10.8% | 18.5% | ||
| Q4 24 | 11.5% | 24.1% | ||
| Q3 24 | 10.4% | 22.2% | ||
| Q2 24 | 9.4% | 23.4% | ||
| Q1 24 | 8.7% | 19.2% |
每股收益（稀释后）COOMTD
| Q4 25 | $0.42 | $13.91 | ||
| Q3 25 | $0.49 | $10.57 | ||
| Q2 25 | $0.44 | $9.76 | ||
| Q1 25 | $0.52 | $7.81 | ||
| Q4 24 | $0.59 | $11.91 | ||
| Q3 24 | $0.52 | $9.96 | ||
| Q2 24 | $0.44 | $10.37 | ||
| Q1 24 | $0.41 | $8.24 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $110.6M | — |
| 总债务越低越好 | $2.5B | $2.1B |
| 股东权益账面价值 | $8.2B | $-23.6M |
| 总资产 | $12.4B | $3.7B |
| 负债/权益比越低杠杆越低 | 0.30× | — |
8季度趋势，按日历期对齐
现金及短期投资COOMTD
| Q4 25 | $110.6M | — | ||
| Q3 25 | $124.9M | $69.1M | ||
| Q2 25 | $116.2M | $61.8M | ||
| Q1 25 | $100.9M | — | ||
| Q4 24 | $107.6M | $59.4M | ||
| Q3 24 | $109.7M | $71.6M | ||
| Q2 24 | $112.4M | $70.8M | ||
| Q1 24 | $135.2M | — |
总债务COOMTD
| Q4 25 | $2.5B | $2.1B | ||
| Q3 25 | $2.4B | $2.1B | ||
| Q2 25 | $2.5B | $2.1B | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.6B | $1.8B | ||
| Q3 24 | $2.6B | $1.9B | ||
| Q2 24 | $2.7B | $1.7B | ||
| Q1 24 | $2.7B | — |
股东权益COOMTD
| Q4 25 | $8.2B | $-23.6M | ||
| Q3 25 | $8.4B | $-249.2M | ||
| Q2 25 | $8.3B | $-258.8M | ||
| Q1 25 | $8.1B | $-182.0M | ||
| Q4 24 | $8.1B | $-126.9M | ||
| Q3 24 | $7.9B | $-154.4M | ||
| Q2 24 | $7.8B | $-152.8M | ||
| Q1 24 | $7.7B | $-158.7M |
总资产COOMTD
| Q4 25 | $12.4B | $3.7B | ||
| Q3 25 | $12.4B | $3.5B | ||
| Q2 25 | $12.4B | $3.4B | ||
| Q1 25 | $12.2B | $3.2B | ||
| Q4 24 | $12.3B | $3.2B | ||
| Q3 24 | $12.1B | $3.3B | ||
| Q2 24 | $12.0B | $3.2B | ||
| Q1 24 | $12.0B | $3.3B |
负债/权益比COOMTD
| Q4 25 | 0.30× | — | ||
| Q3 25 | 0.29× | — | ||
| Q2 25 | 0.30× | — | ||
| Q1 25 | 0.31× | — | ||
| Q4 24 | 0.32× | — | ||
| Q3 24 | 0.33× | — | ||
| Q2 24 | 0.34× | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $247.9M | $225.6M |
| 自由现金流经营现金流 - 资本支出 | $149.9M | $184.1M |
| 自由现金流率自由现金流/营收 | 14.1% | 16.3% |
| 资本支出强度资本支出/营收 | 9.2% | 3.7% |
| 现金转化率经营现金流/净利润 | 2.93× | 0.79× |
| 过去12个月自由现金流最近4个季度 | $433.7M | $848.6M |
8季度趋势，按日历期对齐
经营现金流COOMTD
| Q4 25 | $247.9M | $225.6M | ||
| Q3 25 | $261.4M | $299.4M | ||
| Q2 25 | $96.2M | $236.4M | ||
| Q1 25 | $190.6M | $194.4M | ||
| Q4 24 | $268.1M | $266.2M | ||
| Q3 24 | $207.5M | $254.7M | ||
| Q2 24 | $111.0M | $257.5M | ||
| Q1 24 | $122.7M | $190.0M |
自由现金流COOMTD
| Q4 25 | $149.9M | $184.1M | ||
| Q3 25 | $164.5M | $274.9M | ||
| Q2 25 | $18.1M | $212.5M | ||
| Q1 25 | $101.2M | $177.2M | ||
| Q4 24 | $128.1M | $224.9M | ||
| Q3 24 | $118.5M | $233.2M | ||
| Q2 24 | $36.9M | $233.7M | ||
| Q1 24 | $4.6M | $172.6M |
自由现金流率COOMTD
| Q4 25 | 14.1% | 16.3% | ||
| Q3 25 | 15.5% | 26.7% | ||
| Q2 25 | 1.8% | 21.6% | ||
| Q1 25 | 10.5% | 20.1% | ||
| Q4 24 | 12.6% | 21.5% | ||
| Q3 24 | 11.8% | 24.4% | ||
| Q2 24 | 3.9% | 24.7% | ||
| Q1 24 | 0.5% | 18.6% |
资本支出强度COOMTD
| Q4 25 | 9.2% | 3.7% | ||
| Q3 25 | 9.1% | 2.4% | ||
| Q2 25 | 7.8% | 2.4% | ||
| Q1 25 | 9.3% | 2.0% | ||
| Q4 24 | 13.7% | 3.9% | ||
| Q3 24 | 8.9% | 2.2% | ||
| Q2 24 | 7.9% | 2.5% | ||
| Q1 24 | 12.7% | 1.9% |
现金转化率COOMTD
| Q4 25 | 2.93× | 0.79× | ||
| Q3 25 | 2.66× | 1.38× | ||
| Q2 25 | 1.10× | 1.17× | ||
| Q1 25 | 1.83× | 1.19× | ||
| Q4 24 | 2.28× | 1.06× | ||
| Q3 24 | 1.98× | 1.20× | ||
| Q2 24 | 1.25× | 1.16× | ||
| Q1 24 | 1.51× | 1.07× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
COO
| Sphere Other | $365.0M | 34% |
| Toric And Multifocal | $344.7M | 32% |
| Office And Surgical | $214.5M | 20% |
| Fertility | $140.9M | 13% |
MTD
| Products | $857.0M | 76% |
| Services | $272.8M | 24% |
